TRAIL-mediated signaling in prostate, bladder and renal cancer

Nature Reviews Urology

Volumn 8, Issue 8, 2011, Pages 417-427

  Voelkel Johnson, Christina ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BERBERINE; CELASTROL; CELECOXIB; CHETOMIN; CISPLATIN; CURCUMIN; CYSTAMINE; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DIHYDROARTEMISININ; IOI 42; LEXATUMUMAB; MAPATUMUMAB; MATAIRESINOL; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; OZARELIX; PROTEIN BCL 2; PROTEIN INHIBITOR; QUERCETIN; RESVERATROL; ROSIGLITAZONE; SH122; TRICIRIBINE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; WOGONIN;

ANDROGEN THERAPY; APOPTOSIS; BLADDER CARCINOMA; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CANCER SURGERY; CASTRATION; CRYOTHERAPY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; KIDNEY CARCINOMA; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; GENE THERAPY; HUMANS; KIDNEY NEOPLASMS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; URINARY BLADDER NEOPLASMS; UROGENITAL NEOPLASMS;

EID: 80051694782     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2011.81     Document Type: Review

References (129)

1. Pitti, R. M. et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271, 12687-12690 (1996). (Pubitemid 26175834)
2. Wiley, S. R. et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673-682 (1995). (Pubitemid 26091143)
3. Ashkenazi, A., Holland, P. & Eckhardt, S. G. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J. Clin. Oncol. 26, 3621-3630 (2008).
4. Kelley, S. K. et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp. Ther. 299, 31-38 (2001). (Pubitemid 32905115)
5. Griffith, T. S. et al. TRAIL gene therapy: from preclinical development to clinical application. Curr. Gene Ther. 9, 9-19 (2009).
6. Bellail, A. C., Qi, L., Mulligan, P., Chhabra, V. & Hao, C. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev. Recent Clin. Trials 4, 34-41 (2009).
7. Herbst, R. S. et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J. Clin. Oncol. 28, 2839-2846 (2010).
8. Camidge, D. R. et al. A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin. Cancer Res. 16, 1256-1263 (2010).
9. Younes, A. et al. A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. Br. J. Cancer 103, 1783-1787 (2010).
10. Niyazi, M. et al. Efficacy of triple therapies including ionising radiation, agonistic TRAIL antibodies and cisplatin. Oncol. Rep. 21, 1455-1460 (2009).
11. Norian, L. A., James, B. R. & Griffith, T. S. Advances in viral vector-based TRAIL gene therapy for cancer. Cancers 3, 603-620 (2011).
12. Newsom-Davis, T., Prieske, S. & Walczak, H. Is TRAIL the holy grail of cancer therapy? Apoptosis 14, 607-623 (2009).
13. Hymowitz, S. G. et al. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 39, 633-640 (2000). (Pubitemid 30065031)
14. Marsters, S. A. et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 7, 1003-1006 (1997). (Pubitemid 28017080)
15. Sheridan, J. P. et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277, 818-821 (1997). (Pubitemid 27366733)
16. Emery, J. G. et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273, 14363-14367 (1998). (Pubitemid 28319153)
17. Pennarun, B. et al. Playing the DISC: turning on TRAIL death receptor-mediated apoptosis in cancer. Biochim. Biophys. Acta 1805, 123-140 (2010).
18. Scaffidi, C. et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17, 1675-1687 (1998). (Pubitemid 28119121)
19. Garcia-Saez, A. J., Fuertes, G., Suckale, J. & Salgado, J. Permeabilization of the outer mitochondrial membrane by Bcl-2 proteins. Adv. Exp. Med. Biol. 677, 91-105 (2010).
20. Tait, S. W. & Green, D. R. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat. Rev. Mol. Cell Biol. 11, 621-632 (2010).
21. Altieri, D. C. Survivin and IAP proteins in cell-death mechanisms. Biochem. J. 430, 199-205 (2010).
22. Yang, A., Wilson, N. S. & Ashkenazi, A. Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation. Curr. Opin. Cell Biol. 22, 837-844 (2010).
23. Wajant, H. et al. Differential activation of TRAIL-R1 and-2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 20, 4101-4106 (2001). (Pubitemid 32681615)
24. Kelley, R. F. et al. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J. Biol. Chem. 280, 2205-2212 (2005).
25. Wilson, N. S. et al. An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 19, 101-113 (2011).
26. MacFarlane, M. et al. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ. 12, 773-782 (2005). (Pubitemid 40945984)
27. Falschlehner, C., Schaefer, U. & Walczak, H. Following TRAIL's path in the immune system. Immunology 127, 145-154 (2009).
28. Zerafa, N. et al. Cutting edge: TRAIL deficiency accelerates hematological malignancies. J. Immunol. 175, 5586-5590 (2005). (Pubitemid 41508035)
29. Cretney, E. et al. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. 168, 1356-1361 (2002). (Pubitemid 34094506)
30. Takeda, K. et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. 195, 161-169 (2002). (Pubitemid 34461260)
31. Sedger, L. M. et al. Characterization of the in vivo function of TNF-alpha-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice. Eur. J. Immunol. 32, 2246-2254 (2002). (Pubitemid 34965887)
32. Seki, N. et al. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. Cancer Res. 63, 207-213 (2003). (Pubitemid 36070441)
33. Park, S. W., Kim, M. S., Lee, J. Y., Yoo, N. J. & Lee, S. H. Mutational analysis of death receptor genes Fas, TRAILR1 and TRAILR2 in prostate carcinomas. APMIS 118, 615-616 (2010).
34. Langsenlehner, T. et al. The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases. Prostate 68, 264-268 (2008). (Pubitemid 351273055)
35. Koksal, I. T., Sanlioglu, A. D., Karacay, B., Griffith, T. S. & Sanlioglu, S. Tumor necrosis factor-related apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostate-specific antigen recurrence, and decreased survival in patients with prostate carcinoma. Urol. Oncol. 26, 158-165 (2008). (Pubitemid 351288560)
36. Anees, M. et al. Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression. Cancer 117, 1172-1182 (2011).
37. Koksal, I. T., Sanlioglu, A. D., Kutlu, O. & Sanlioglu, S. Effects of androgen ablation therapy in TRAIL death ligand and its receptors expression in advanced prostate cancer. Urol. Int. 84, 445-451 (2010).
38. Raclaw, K. A., Heemers, H. V., Kidd, E. M., Dehm, S. M. & Tindall, D. J. Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosis. Prostate 68, 1696-1706 (2008).
39. Thompson, I. et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J. Urol. 177, 2106-2131 (2007). (Pubitemid 46726449)
40. Mottet, N. et al. EAU Guidelines on Prostate Cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 59, 572-583 (2011).
41. Lawton, C. A. et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int. J. Radiat. Oncol. Biol. Phys. 49, 937-946 (2001). (Pubitemid 32184600)
42. Bolla, M. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360, 103-106 (2002).
43. Hanks, G. E. et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J. Clin. Oncol. 21, 3972-3978 (2003). (Pubitemid 46606211)
44. Shankar, S., Singh, T. R. & Srivastava, R. K. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: intracellular mechanisms. Prostate 61, 35-49 (2004). (Pubitemid 39095693)
45. Abedinpour, P., Baron, V. T., Welsh, J. & Borgstrom, P. Regression of prostate tumors upon combination of hormone ablation therapy and celecoxib in vivo. Prostate 71, 813-823 (2011).
46. Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277-300 (2010).
47. Jacobs, B. L., Lee, C. T. & Montie, J. E. Bladder cancer in 2010: how far have we come? CA Cancer J. Clin. 60, 244-272 (2010).
48. Adams, J., Cuthbert-Heavens, D., Bass, S. & Knowles, M. A. Infrequent mutation of TRAIL receptor 2 (TRAIL-R2/DR5) in transitional cell carcinoma of the bladder with 8p21 loss of heterozygosity. Cancer Lett. 220, 137-144 (2005). (Pubitemid 40568770)
49. Wang, M., Cheng, G., Zhang, Z. & Fu, G. Genetic variants in the death receptor 4 gene contribute to susceptibility to bladder cancer. Mutat. Res. 661, 85-92 (2009).
50. Hazra, A. et al. Death receptor 4 and bladder cancer risk. Cancer Res. 63, 1157-1159 (2003). (Pubitemid 36348687)
51. Ludwig, A. T. et al. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guerin-induced antitumor activity. Cancer Res. 64, 3386-3390 (2004). (Pubitemid 38657909)
52. Rosevear, H. M., Lightfoot, A. J., O'Donnell, M. A. & Griffith, T. S. The role of neutrophils and TNF-related apoptosis-inducing ligand (TRAIL) in bacillus Calmette-Guerin (BCG) immunotherapy for urothelial carcinoma of the bladder. Cancer Metastasis Rev. 28, 345-353 (2009).
53. Macher-Goeppinger, S. et al. Prognostic value of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors in renal cell cancer. Clin. Cancer Res. 15, 650-659 (2009).
54. Baader, E. et al. Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects. Cancer Res. 65, 7888-7895 (2005). (Pubitemid 41297266)
55. Levina, V., Marrangoni, A. M., DeMarco, R., Gorelik, E. & Lokshin, A. E. Multiple effects of TRAIL in human carcinoma cells: induction of apoptosis, senescence, proliferation, and cytokine production. Exp. Cell Res. 314, 1605-1616 (2008).
56. Hoogwater, F. J. et al. Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells. Gastroenterology 138, 2357-2367 (2010).
57. Gattenlohner, S., Etschmann, B., Riedmiller, H. & Muller-Hermelink, H. K. Lack of KRAS and BRAF mutation in renal cell carcinoma. Eur. Urol. 55, 1490-1491 (2009).
58. Zantl, N. et al. Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance. Oncogene 26, 7038-7048 (2007). (Pubitemid 350014613)
59. Kallio, J. P. et al. Renal cell carcinoma MIB-1, Bax and Bcl-2 expression and prognosis. J. Urol. 172, 2158-2161 (2004). (Pubitemid 39507482)
60. Gobe, G., Rubin, M., Williams, G., Sawczuk, I. & Buttyan, R. Apoptosis and expression of Bcl-2, Bcl-XL, and Bax in renal cell carcinomas. Cancer Invest. 20, 324-332 (2002). (Pubitemid 34496565)
61. Meteoglu, I., Erdogdu, I. H., Meydan, N., Erkus, M. & Barutca, S. NF-KappaB expression correlates with apoptosis and angiogenesis in clear cell renal cell carcinoma tissues. J. Exp. Clin. Cancer Res. 27, 53 (2008).
62. Oya, M. et al. Increased nuclear factor-kappa B activation is related to the tumor development of renal cell carcinoma. Carcinogenesis 24, 377-384 (2003). (Pubitemid 36432631)
63. Trauzold, A. et al. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 25, 7434-7439 (2006). (Pubitemid 44853434)
64. Ikeda, T. et al. Dual effects of TRAIL in suppression of autoimmunity: the inhibition of Th1 cells and the promotion of regulatory T cells. J. Immunol. 185, 5259-5267 (2010).
65. Li, J. F. et al. The prognostic value of peritumoral regulatory T cells and its correlation with intratumoral cyclooxygenase-2 expression in clear cell renal cell carcinoma. BJU Int. 103, 399-405 (2009).
66. Adotevi, O. et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based anti-angiogenic therapy in metastatic renal cancer patients. J. Immunother. 33, 991-998 (2010).
67. Desar, I. M. et al. Sorafenib reduces the percentage of tumor infiltrating regulatory T cells in renal cell carcinoma patients. Int. J. Cancer doi:10.1002/ijc.25674.
68. Wu, X. X. & Kakehi, Y. Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner. Clin. Cancer Res. 15, 2039-2047 (2009).
69. Song, J. H., Song, D. K., Herlyn, M., Petruk, K. C. & Hao, C. Cisplatin downregulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human melanoma cells. Clin. Cancer Res. 9, 4255-4266 (2003). (Pubitemid 37204047)
70. Mirandola, P. et al. Anticancer agents sensitize osteosarcoma cells to TNF-related apoptosis-inducing ligand downmodulating IAP family proteins. Int. J. Oncol. 28, 127-133 (2006).
71. Kim, Y. H. & Lee, Y. J. Time sequence of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin treatment is responsible for a complex pattern of synergistic cytotoxicity. J. Cell Biochem. 98, 1284-1295 (2006). (Pubitemid 44128366)
72. White-Gilbertson, S. J. et al. Oxidative stress sensitizes bladder cancer cells to TRAIL mediated apoptosis by downregulating anti-apoptotic proteins. J. Urol. 182, 1178-1185 (2009).
73. Wang, S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 27, 6207-6215 (2008).
74. Niemoller, O. & Belka, C. Targeting death-receptors in radiation therapy. Results Probl. Cell Differ. 49, 219-239 (2009).
75. Shirley, S. & Micheau, O. Targeting c-FLIP in cancer. Cancer Lett. doi:10.1016/j.canlet.2010.10.009.
76. White-Gilbertson, S., Rubinchik, S. & Voelkel-Johnson, C. Transformation, translation and TRAIL: an unexpected intersection. Cytokine Growth Factor Rev. 19, 167-172 (2008).
77. Jang, J. H., Park, J. S., Lee, T. J. & Kwon, T. K. Transglutaminase 2 expression levels regulate sensitivity to cystamine plus TRAIL-mediated apoptosis. Cancer Lett. 287, 224-230 (2010).
78. Jang, J. H. et al. Compound C sensitizes Caki renal cancer cells to TRAIL-induced apoptosis through reactive oxygen species-mediated downregulation of c-FLIPL and Mcl-1. Exp. Cell Res. 316, 2194-2203 (2010).
79. Rokhlin, O. W., Guseva, N. V., Taghiyev, A. F., Glover, R. A. & Cohen, M. B. KN-93 inhibits androgen receptor activity and induces cell death irrespective of p53 and Akt status in prostate cancer. Cancer Biol. Ther. 9, 224-235 (2010).
80. Song, J. H., Kandasamy, K. & Kraft, A. S. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J. Biol. Chem. 283, 25003-25013 (2008).
81. Fan, S., Meng, Q., Laterra, J. J. & Rosen, E. M. Scatter factor protects tumor cells against apoptosis caused by TRAIL. Anticancer Drugs 21, 10-24 (2010).
82. Tang, X., Sun, Y. J., Half, E., Kuo, M. T. & Sinicrope, F. Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res. 62, 4903-4908 (2002). (Pubitemid 34984412)
83. Chen, Q. et al. Potent antitumor activity in experimental hepatocellular carcinoma by adenovirus-mediated co-expression of TRAIL and shRNA against COX-2. Clin. Cancer Res. 16, 3696-3705 (2010).
84. Chen, D. J. & Huerta, S. Smac mimetics as new cancer therapeutics. Anticancer Drugs 20, 646-658 (2009).
85. Vince, J. E. et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 131, 682-693 (2007). (Pubitemid 350103599)
86. Metwalli, A. R. et al. Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells. Cancer Biol. Ther. 10, 885-892 (2010).
87. Griffith, T. S. et al. Sensitization of human bladder tumor cells to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis with a small molecule IAP antagonist. Apoptosis 16, 13-26 (2010).
88. Dai, Y. et al. A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB. BMC Cancer 9, 392 (2009).
89. Yano, K. et al. Chetomin induces degradation of XIAP and enhances TRAIL sensitivity in urogenital cancer cells. Int. J. Oncol. 38, 365-374 (2010).
90. Qiu, J. et al. Potentiation of tumor necrosis factor-alpha-induced tumor cell apoptosis by a small molecule inhibitor for anti-apoptotic protein hPEBP4. J. Biol. Chem. 285, 12241-12247 (2010).
91. Li, H. et al. hPEBP4 resists TRAIL-induced apoptosis of human prostate cancer cells by activating Akt and deactivating ERK1/2 pathways. J. Biol. Chem. 282, 4943-4950 (2007). (Pubitemid 47100993)
92. Fiory, F., Formisano, P., Perruolo, G. & Beguinot, F. Frontiers: PED/PEA-15, a multifunctional protein controlling cell survival and glucose metabolism. Am. J. Physiol. Endocrinol. Metab. 297, E592-E601 (2009).
93. Panner, A., James, C. D., Berger, M. S. & Pieper, R. O. mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol. Cell Biol. 25, 8809-8823 (2005). (Pubitemid 41429073)
94. Bortul, R. et al. Constitutively active Akt1 protects HL60 leukemia cells from TRAIL-induced apoptosis through a mechanism involving NF-kappaB activation and cFLIP(L) upregulation. Leukemia 17, 379-389 (2003). (Pubitemid 36266916)
95. Panka, D. J., Mano, T., Suhara, T., Walsh, K. & Mier, J. W. Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. J. Biol. Chem. 276, 6893-6896 (2001).
96. Dieterle, A. et al. The Akt inhibitor triciribine sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Int. J. Cancer 125, 932-941 (2009).
97. Jacquemin, G., Shirley, S. & Micheau, O. Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells? Cell. Mol. Life Sci. 67, 3115-3130 (2010).
98. Ishibashi, M. & Ohtsuki, T. Studies on search for bioactive natural products targeting TRAIL signaling leading to tumor cell apoptosis. Med. Res. Rev. 28, 688-714 (2008).
99. Szliszka, E. & Krol, W. The role of dietary polyphenols in tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-induced apoptosis for cancer chemoprevention. Eur. J. Cancer Prev. 20, 63-69 (2011).
100. Ganapathy, S., Chen, Q., Singh, K. P., Shankar, S. & Srivastava, R. K. Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor. PLoS ONE 5, e15627 (2010).
101. Chen, Q., Ganapathy, S., Singh, K. P., Shankar, S. & Srivastava, R. K. Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells. PLoS ONE 5, e15288 (2010).
102. Andrzejewski, T. et al. Therapeutic efficacy of curcumin/TRAIL combination regimen for hormone-refractory prostate cancer. Oncol. Res. 17, 257-267 (2008).
103. Shankar, S., Ganapathy, S., Chen, Q. & Srivastava, R. K. Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis. Mol. Cancer 7, 16 (2008).
104. Teiten, M. H., Gaascht, F., Eifes, S., Dicato, M. & Diederich, M. Chemopreventive potential of curcumin in prostate cancer. Genes Nutr. 5, 61-74 (2010).
105. Kamat, A. M., Tharakan, S. T., Sung, B. & Aggarwal, B. B. Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors. Cancer Res. 69, 8958-8966 (2009).
106. Plantivaux, A., Szegezdi, E., Samali, A. & Egan, L. Is there a role for nuclear factor kappaB in tumor necrosis factor-related apoptosis-inducing ligand resistance? Ann. NY Acad. Sci. 1171, 38-49 (2009).
107. Lee, D. H., Rhee, J. G. & Lee, Y. J. Reactive oxygen species upregulate p53 and Puma; a possible mechanism for apoptosis during combined treatment with TRAIL and wogonin. Br. J. Pharmacol. 157, 1189-1202 (2009).
108. Gallenne, T. et al. Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members. J. Cell Biol. 185, 279-290 (2009).
109. Chipuk, J. E. & Green, D. R. PUMA cooperates with direct activator proteins to promote mitochondrial outer membrane permeabilization and apoptosis. Cell Cycle 8, 2692-2696 (2009).
110. Tang, Y. et al. Flavokawain B, a kava chalcone, induces apoptosis via upregulation of death-receptor 5 and Bim expression in androgen receptor negative, hormonal refractory prostate cancer cell lines and reduces tumor growth. Int. J. Cancer 127, 1758-1768 (2010).
111. Szliszka, E., Czuba, Z. P., Mazur, B., Paradysz, A. & Krol, W. Chalcones and dihydrochalcones augment TRAIL-mediated apoptosis in prostate cancer cells. Molecules 15, 5336-5353 (2010).
112. Chen, Y. C. et al. Cryptocaryone, a natural dihydrochalcone, induces apoptosis in human androgen independent prostate cancer cells by death receptor clustering in lipid raft and nonraft compartments. J. Urol. 183, 2409-2418 (2010).
113. Min, Y. et al. Death receptor 5-recruited raft components contributes to the sensitivity of Jurkat leukemia cell lines to TRAIL-induced cell death. IUBMB Life 61, 261-267 (2009).
114. Xu, L. et al. Oxaliplatin enhances TRAIL-induced apoptosis in gastric cancer cells by CBL-regulated death receptor redistribution in lipid rafts. FEBS Lett. 583, 943-948 (2009).
115. Jung, Y. H., Heo, J., Lee, Y. J., Kwon, T. K. & Kim, Y. H. Quercetin enhances TRAIL-induced apoptosis in prostate cancer cells via increased protein stability of death receptor 5. Life Sci. 86, 351-357 (2010).
116. Szliszka, E. et al. Ethanolic extract of Brazilian green propolis sensitizes prostate cancer cells to TRAIL-induced apoptosis. Int. J. Oncol. 38, 941-953 (2011).
117. Cavin, C. et al. Cafestol and kahweol, two coffee specific diterpenes with anticarcinogenic activity. Food Chem. Toxicol. 40, 1155-1163 (2002). (Pubitemid 34626880)
118. Um, H. J. et al. The coffee diterpene kahweol sensitizes TRAIL-induced apoptosis in renal carcinoma Caki cells through downregulation of Bcl-2 and c-FLIP. Chem. Biol. Interact. 186, 36-42 (2010).
119. Yang, H., Chen, D., Cui, Q. C., Yuan, X. & Dou, Q. P. Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res. 66, 4758-4765 (2006).
120. Sung, B., Park, B., Yadav, V. R. & Aggarwal, B. B. Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the downregulation of cell survival proteins and upregulation of death receptors. J. Biol. Chem. 285, 11498-11507 (2010).
121. Lee, S. J. et al. Berberine sensitizes TRAIL-induced apoptosis through proteasome-mediated downregulation of c-FLIP and Mcl-1 proteins. Int. J. Oncol. 38, 485-492 (2010).
122. Peuhu, E. et al. Inhibition of Akt signaling by the lignan matairesinol sensitizes prostate cancer cells to TRAIL-induced apoptosis. Oncogene 29, 898-908 (2010).
123. Festuccia, C. et al. Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors. Prostate 70, 1340-1349 (2010).
124. He, Q. et al. Dihydroartemisinin upregulates death receptor 5 expression and cooperates with TRAIL to induce apoptosis in human prostate cancer cells. Cancer Biol. Ther. 9, 819-824 (2010).
125. Day, C. Thiazolidinediones: a new class of antidiabetic drugs. Diabet. Med. 16, 179-192 (1999).
126. Lehmann, J. M. et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270, 12953-12956 (1995).
127. Plissonnier, M. L., Fauconnet, S., Bittard, H. & Lascombe, I. Insights on distinct pathways of thiazolidinediones (PPARgamma ligand)-promoted apoptosis in TRAIL-sensitive or-resistant malignant urothelial cells. Int. J. Cancer 127, 1769-1784 (2010).
128. Zaman, M. S. et al. The functional significance of microRNA-145 in prostate cancer. Br. J. Cancer 103, 256-264 (2010).
129. Lu, Q. et al. MicroRNA-221 silencing predisposed human bladder cancer cells to undergo apoptosis induced by TRAIL. Urol. Oncol. 28, 635-641 (2010).